12 July 2016 - PHARMAC is seeking feedback on a provisional agreement with Mylan New Zealand Limited for the listing of Mylan’s brands of zoledronic acid injection 4 mg per 5 ml vial and vecuronium bromide injection 10 mg vial.

In summary, this proposal would result in:

• Zoledronic acid injection 4 mg per 5 ml vial (Zoledronic Alphapharm) being funded from 1 September 2016 subject to the same Special Authority criteria and DHB hospital restrictions as the Zometa brand for patients with hypercalcaemia of malignancy or bone metastases.
• Vecuronium bromide injection 10 mg vial (Vecuronium Bromide Alphapharm) being listed in Part II of Section H of the Pharmaceutical Schedule for use as an adjunct to general anaesthesia, as soon as possible following Medsafe approval.
  Vecuronium bromide injection 4 mg ampoule being delisted from Part II of Section H of the Pharmaceutical Schedule from 1 September 2016.

View PHARMAC Consultation